Alex's Lemonade Stand Foundation for Childhood Cancer

Collaborators

Alejandro Sweet-Cordero, MD, University of California, San Francisco
Richard Gorlick, MD, MD Anderson Cancer Center

Background

Most patients having high-risk neuroblastoma (NBL)--primarily a childhood cancer--do not achieve long-term survival and eventually succumb to an incurable disease recurrence. Further, the limited involvement of pharmaceutical companies and small patient cohorts hinder the development of new drugs for pediatric cancers.